An ankle-foot orthosis includes a leg portion and a foot portion. The foot portion is biased toward an equilibrium angle with respect to the leg portion, and the equilibrium angle is adjustable to accommodate different users' natural stance. An adjustable leg stay permits fitting the orthosis to multiple different users, and the orthosis can be fitted to either leg of a user with only a foot plate change. A variable stiffness spring and cam system modulate ankle joint stiffness according to a pre-defined cam profile. The contact point of the cam system is forward of the user's heel and thus closer to the ankle joint, enabling reduced-size components. Two rotational degrees of freedom are provided in plantarflexion/dorsiflexion and inversion/eversion.
A61F 5/01 - Orthopaedic devices, e.g. long-term immobilising or pressure directing devices for treating broken or deformed bones such as splints, casts or braces
A gear set comprising an input shaft, an output shaft, a gear; and a friction pad. In a first configuration, the gear set has a first gear ratio for the input shaft rotational speed to the output shaft rotational speed equal to N:1, where N is not equal to 1. In the first configuration, the gear rotates relative to the friction pad. In a second configuration, the gear set has a gear ratio for the input shaft rotational speed to the output shaft rotational speed equal to 1:1, wherein the friction pad prevents rotation of the gear relative to the friction pad.
F16H 3/10 - Toothed gearings for conveying rotary motion with variable gear ratio or for reversing rotary motion without gears having orbital motion exclusively or essentially with continuously- meshing gears, that can be disengaged from their shafts with one or more one-way clutches as an essential feature
The present disclosure relates to methods for assessing metabolic flux. In some aspects, the disclosure relates to methods for estimating absolute metabolic flux for a pathway of interest based upon a level of one or more metabolites and/or isotopologues thereof at a single point in time following administration of a tracer to a subject. In some embodiments, the methods described herein are performed or generated using artificial intelligence/machine-learning (AI/ML) models.
A probe assembly and method of manufacture includes probe shanks having a bend at a hinge to conform around a core region. In some embodiments, the probe shank has multiple probe sub-units which include magnets shielded from electrodes on the probe shank. Attaching the magnetized probe sub-units and/or conforming the probe shanks around a core region can include capillary induced adherence. In some embodiments, the probe assemblies and methods of manufacture overcome challenges of a monolithic fabrication process.
Provided herein are methods, compositions, reaction mixtures, kits and systems for measuring protease activities, detecting protein-protein interactions, and identifying signaling molecules that induce protein-protein interactions. In particular, provided herein are methods, compositions, reaction mixtures, kits and systems with a reporter motif comprising cleavage of acid-base coils-caged enhanced ascorbate peroxidase (APEX).
The present disclosure relates to gene panels, materials, and methods for evaluation of cancer in a subject. In particular, provided herein are synthetic scaffolds and methods of use thereof for predicting or monitoring response to an immune checkpoint inhibitor in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
An excitonic device includes a substrate and nanowires coupled to the substrate. Electrons and holes are spatially confined within an active region of each nanowire. The nanowires are operable for electroluminescent emission originating from excitons comprising bound states of electrons and holes in the active region of each nanowire.
H01L 33/20 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular shape, e.g. curved or truncated substrate
H01L 33/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies
H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 27/15 - Devices consisting of a plurality of semiconductor or other solid-state components formed in or on a common substrate including semiconductor components with at least one potential-jump barrier or surface barrier, specially adapted for light emission
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Burke, Martin, D.
Ekaputri, Stella
Brown, Samantha, Taylor
Schroeder, Nathan, Eric
Seo, Young, Ah
Abstract
Disclosed is a method of treating a disease or condition characterized by neurodegeneration via administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting of hinokitiol, hinokitiol derivatives, and iron-transporting tropolones.
9.
COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISEASE
Provided herein are compositions and methods for treating and/or preventing inflammatory disease. In particular, provided herein are non mucin degrading bacteria and their use in treating and/or preventing inflammatory disease (e.g., GvHD).
A power conversion device may perform model-referenced power processing for multiple power nodes connected at one or more power ports. The power conversion device may include binning logic to bin the occupied ports according to their estimated condition of the occupying nodes within a pre-defined condition model for an expected population of power nodes. The binning logic then interconnects the binned ports to lite and sparse layer nodes in accordance with the occupancy and binning.
H02M 1/00 - APPARATUS FOR CONVERSION BETWEEN AC AND AC, BETWEEN AC AND DC, OR BETWEEN DC AND DC, AND FOR USE WITH MAINS OR SIMILAR POWER SUPPLY SYSTEMS; CONVERSION OF DC OR AC INPUT POWER INTO SURGE OUTPUT POWER; CONTROL OR REGULATION THEREOF - Details of apparatus for conversion
H02M 3/04 - Conversion of dc power input into dc power output without intermediate conversion into ac by static converters
G06N 3/04 - Architecture, e.g. interconnection topology
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Wang, Shaomeng
Leng, Lingying
Tu, Wenbin
Yang, Lin
Wang, Mi
Kirchhoff, Paul
Xu, Guozhang
Li, Zhenwu
Tosovic, Jelena
Stuckey, Jeanne
Abstract
Described herein are compounds and conjugates of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 inhibitors or degraders).
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
12.
COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF
ONCOPIA THERAPEUTICS, INC. d/b/a/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Wang, Shaomeng
Leng, Lingying
Yang, Lin
Tu, Wenbin
Huang, Liyue
Wang, Mi
Jiang, Wei
Kirchhoff, Paul
Xu, Guozhang
Li, Zhenwu
Harikrishnan, Lalgudi
Priestley, E., Scott
Tosovic, Jelena
Stuckey, Jeanne
Abstract
Described herein are compounds of Formula II and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as SMARCA2 or SMARCA4 degraders).
A61K 31/517 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
13.
METHODS, DEVICES, AND SYSTEMS FOR TREATING BONE DEFECTS
Provided herein are devices, systems, and methods of treating bone defects by wrapping thermoplastics around bone and molding thermoplastic to bone. Also provided herein are a sonotrode coupler and system used to perform the method. The technology provides devices, systems, and methods for containment of graft materials, matrices, and bone regenerative therapeutics and prevents surrounding tissue encroachment for guided bone regeneration.
Provided herein are systems and methods for identifying collateral lethal genes via metabolic fluxes and the use of such genes for the identification of, selections of, and use of therapeutic agents. Further provided herein are identified targets, such as MTHFD2, that may be regulated to treat or prevent diseases and conditions.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
The present disclosure provides methods, systems, and non-transitory computer-readable media for identifying efficient chemical synthesis processes, using molecular graph editing.
The invention disclosed herein generally relates to methods and systems for growing, expanding and/or obtaining human intestinal organoids (HIOs) having a serosal mesothelial layer. In particular, the invention disclosed herein relates to methods and systems for culturing hindgut spheroid tissue in suspension to obtain HIOs having an organized serosal mesothelial layer that is similar to primary human intestinal serosal mesothelium.
The disclosure relates to microparticles and nanoparticles comprising a polymer matrix comprising an uncapped polymer and a net positively charged therapeutic agent at neutral pH. More particularly the disclosure relates to PLGA and/or PLA particles comprising an uncapped polymer for extended, controlled release of positively charged proteins or peptides at neutral pH. Methods of making the particles and administering the particles are also provided.
An optical phased array device and method for manufacturing an optical phased array for the optical phased array device. The method includes: forming a base layer of a waveguide array on a base substrate, determining a waveguide pattern defining a plurality of waveguide paths, and fabricating a pattern layer of the waveguide array on top of the base layer of the waveguide array according to the determined waveguide pattern. The plurality of waveguide paths branch from a common path and terminate at a plurality of edge emitters, where the plurality of edge emitters are spaced apart from one another along a first axis that extends in the first dimension along an edge of the optical phased array. The spacing of multiple ones of the plurality of emitters along the first axis is aperiodic.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
G01S 7/481 - Constructional features, e.g. arrangements of optical elements
19.
COMPOSITIONS AND METHODS FOR GROWING ESOPHAGEAL CELLS AND RELATED USES THEREOF
Improved techniques for maintaining long-term cultures of the healthy and diseased human esophagus established in 2-dimension (2D) and 3-dimension is also needed. The invention disclosed herein generally relates to methods and systems for culturing and expanding esophageal cells with a growth media comprising a rho-kinase inhibitor, a WNT-activator/agonist, EGF, an inhibitor of TGF-BETA signaling, an inhibitor of BMP signaling, and hydrocortisone.
Controlling navigation of an autonomous unmanned aerial vehicle (UAV), commonly known as a drone, involves mathematical modeling and the resulting estimations. The autonomous UAV has one or more rotors, a wind sensor, and a controller for feedforward flight control implementation, per an embodiment. One estimation is of a thrust force at the rotor(s), and another estimation is of a rotor drag force at the rotors(s). Further, the wind sensor takes wind measurements. The wind measurements, the thrust force estimation, and the rotor drag force estimation are all used by the feedforward flight control in order to control navigation of the autonomous UAV. The navigation control can more readily manage flight of the autonomous UAV amid strong crosswinds, wind gusts, heavy winds, and other severe environmental conditions.
The present invention relates to systems, compositions, and methods for altering nucleic acids, such as at a single position (e.g., A/T to G/C or G/C to A/T; in a gene with disease causing SNP). In particular, the present invention relates to engineered CRISPR/Cas systems comprising: a first Cas protein (e.g., Cas5-8 or Cas11) which is optionally tethered or fused to an effector protein selected from: i) an adenine deaminase, ii) a uracil glycosylase inhibitor, or iii) an APOBEC protein; and at least one guide RNA (gRNA) configured to hybridize to a portion of a target nucleic acid sequence. In certain embodiments, the systems further comprise a second Cas protein selected from: i) Cas3, ii) a helicase-deficient Cas3; or iii) a single-strand nicking Cas endonucleases (e.g., Cas9 Nickase H840A Protein).
22 monolayer is achieved using local strain to confine as well as direct exciton transport. An unexpected and massive deviation from the Einstein relation is observed and correlated with the exciton capture by defects. Experiments at elevated exciton densities reveal that the exciton drift velocity monotonically increases with exciton density, unlike exciton mobility, due to contributions from the non-equilibrium many-body effects.
A photocatalytic device includes a substrate and an array of conductive projections supported by the substrate and extending outward from the substrate, each conductive projection of the array of conductive projections having a semiconductor composition configured for photogeneration of charge carriers. Each conductive projection of the array of conductive projections is decorated with a catalyst arrangement. The catalyst arrangement includes metal nanoparticles. The semiconductor composition is doped p-type
A wind sensor and a method of making wind flow direction and wind flow velocity estimations and predictions are set forth. The wind sensor has a spherical shell body, a multitude of pressure taps, and a multitude of pressure transducers. Size, weight, power, and cost (SWaP- C) optimizations can be effected in the design and construction of the wind sensor. An inverse mathematical model, as well as machine learning, are utilized in the wind flow direction and velocity estimations. Compared to past devices, the wind sensor and method exhibit enhanced fidelity.
G01P 5/14 - Measuring speed of fluids, e.g. of air stream; Measuring speed of bodies relative to fluids, e.g. of ship, of aircraft by measuring differences of pressure in the fluid
G01W 1/02 - Instruments for indicating weather conditions by measuring two or more variables, e.g. humidity, pressure, temperature, cloud cover or wind speed
G01W 1/10 - Devices for predicting weather conditions
Provided herein are methods and compositions for treating cancer, particularly the methods and compositions comprising a neuregulin 4 (NRG4) polypeptide.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Jiang, Xiaoning
Xu, Zhen
Zhang, Bohua
Wu, Huaiyu
Kim, Jinwook
Kim, Howuk
Dayton, Paul, Alexander
Goel, Leela
Abstract
A method for sonothrombolysis mediated with contrast agents includes administering at least one contrast agent into a blood vessel of a patient. The method further includes controlling application of ultrasound energy to the at least one contrast agent within the blood vessel, wherein controlling the application of the ultrasound energy includes driving an ultrasound transducer with a signal having a first frequency component and a second frequency component different from the first frequency component.
in vitroin vitro, which was not observed with unmodified scaffolds. Following transplantation, β-cell viability and differentiation were improved with SA-FasL modification. A sustained increase in insulin positive cell ratio was observed with SA-FasL modified relative to unmodified scaffolds. These results demonstrate that SA-FasL-modified scaffolds can mitigate initial inflammatory response and enhance β-cell engraftment and differentiation.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis
C12M 3/02 - Tissue, human, animal or plant cell, or virus culture apparatus with means providing suspensions
Light emitting nanowire devices, in accordance with aspects of the present technology, can include a short period superlattice (SPSL) region underlaying an N-polar multiple quantum well (MQW) region. The short period superlattice (SPSL) region can relax strain in the multiple quantum well (MQW) region. The nanowires can be submicron scale and characterized by red electroluminescence.
H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
H01L 33/18 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular crystal structure or orientation, e.g. polycrystalline, amorphous or porous within the light emitting region
H01L 33/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies
H01L 33/32 - Materials of the light emitting region containing only elements of group III and group V of the periodic system containing nitrogen
H01L 33/00 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof
H01L 33/20 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a particular shape, e.g. curved or truncated substrate
B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
In an on-demand electric charge service, a plurality of mobile power transmitters or donors deliver electric charge to one or a plurality of compatible power receivers, or vice versa. Alternatively, a plurality of mobile power receivers or donors and a plurality of power receivers or recipients form nodes of a peer-to-peer charge service, such as in a hub-spoke or a block-chain configuration. A system and/or method for establishing a charge session in an on-demand electric charge service comprises a request processing unit for receiving a charge session request for one or a plurality of power receivers or one or a plurality of mobile power transmitters, and at least one user dataset or one provider dataset.
B60L 53/38 - Means for automatic or assisted adjustment of the relative position of charging devices and vehicles specially adapted for charging by inductive energy transfer
H02J 50/80 - Circuit arrangements or systems for wireless supply or distribution of electric power involving the exchange of data, concerning supply or distribution of electric power, between transmitting devices and receiving devices
H02J 50/40 - Circuit arrangements or systems for wireless supply or distribution of electric power using two or more transmitting or receiving devices
H02J 50/90 - Circuit arrangements or systems for wireless supply or distribution of electric power involving detection or optimisation of position, e.g. alignment
The present disclosure relates to labeling of proteins for evaluating changes in microtubule structure. Included are compositions and methods that permit detection of shortening and/or lengthening of microtubules for research, diagnostic, and therapeutic purposes.
The disclosure relates to GRAIL-1 peptide products and methods to target mutant p53 for treating p53-mutant related disease conditions such as Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). The disclosure also relates to methods to monitor the therapeutic response of treated BE and EAC patients by detecting expression of epidermal growth factor receptor (EGER) on BE and EAC cells.
C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
Provided herein are methods, compositions, kits and systems for the detection, identification and quantification of bacteria and fungi. In particular, provided herein are methods, compositions, kits and systems comprising oligonucleotide primers that hybridize to sequence regions of nucleic acids flanking ribosomal 16S, 23S, 5S, 18S, 5.8S, and 25-28S internal transcribed spacer regions (ITSs) and other conserved genes from 2 or more different bacteria or fungi, polymerase chain reaction (PCR or qPCR) amplification, high resolution melt curve analysis and amplicon size determination for microbial identification.
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
A method of joining a metal part and a polymer/polymer composite part comprising providing a metal part; providing a polymer or polymer composite part; inserting an insert layer between the metal part and the polymer or polymer composite part; and applying heat to the metal part to a temperature above the melting temperatures and below a degradation temperature of the polymer or polymer composite part and the insert layer and simultaneously applying pressure to the combination of the metal part, the polymer or polymer composite part, and the insert layer to combine the metal part and the polymer or polymer composite part into a joined assembly having a chemical bond therebetween.
ONCOPIA THERAPEUTICS, INC. d.b.a PROTEOVANT THERAPEUTICS, INC. (USA)
REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Xu, Guozhang
Li, Zhenwu
Wang, Shaomeng
Zhang, Xuqing
Abstract
Described herein are compounds and conjugates of Formulae I and II and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as cereblon-binding agents and bifunctional degraders for certain proteins).
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61K 31/4462 - Non-condensed piperidines, e.g. piperocaine only substituted in position 3
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
36.
INDAZOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT (USA)
Inventor
Chen, Zhixiang
Rej, Rohan
Xu, Guozhang
Wu, Dimin
Acharyya, Ranjan, Kumar
Wang, Mingliang
Hu, Biao
Lu, Jianfeng
Wang, Shaomeng
Abstract
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
37.
TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS
ONCOPIA THERAPEUTICS, INC. D/B/A/PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Xu, Gouzhang
Chen, Zhixiang
Rej, Rohan
Acharyya, Ranjan, Kumar
Wu, Dimin
Wang, Mingliang
Hu, Biao
Lu, Jianfeng
Li, Zhenwu
Priestley, E., Scott
Wang, Shaomeng
Abstract
Described herein are compounds of Formula I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as estrogen receptor degraders).
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Provided herein is technology relating to detecting analytes and particularly, but not exclusively, to methods, compositions, systems, and kits for detecting analytes using fluorogenic probes and multiplex technologies.
Provided herein is technology relating to detecting analytes and particularly, but not exclusively, to methods, compositions, systems, and kits for detecting analytes using aptamer technologies.
G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
G01N 33/483 - Physical analysis of biological material
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Wang, Shaomeng
Rej, Rohan
Chen, Zhixiang
Bai, Longchuan
Acharyya, Ranjan, Kumar
Wu, Dimin
Kirchhoff, Paul
Xu, Guozhang
Li, Zhenwu
Abstract
Described herein are compounds or conjugates of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
An implantable multi-photon optical probe includes a probe housing having a proximal end and a distal end implantable on a sample. The probe housing adapted to provide excitation energy to the sample and to collect emitted radiation from the sample. The probe housing includes scanning optics configured to receive excitation radiation, and to laterally and axially scan the excitation radiation over a field-of-view of the optical probe. A scanning lens is disposed in the probe housing configured to receive the excitation radiation from the scanning optics, and an objective lens reshapes and focuses the excitation radiation. A focusing lens is disposed to receive the excitation radiation and to focus the excitation radiation into the sample.
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Rej, Rohan
Chen, Zhixiang
Wang, Mingliang
Wu, Dimin
Xu, Guozhang
Acharyya, Ranjan, Kumar
Hu, Biao
Lu, Jianfeng
Wang, Shaomeng
Abstract
Described herein are compounds of Formula I and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Xu, Guozhang
Acharyya, Ranjan Kumar
Rej, Rohan
Chen, Zhixiang
Hu, Biao
Lu, Jianfeng
Wang, Shaomeng
Abstract
Described herein are compounds of Formula (I) and pharmaceutically acceptable salts, solvates, or stereoisomers thereof, as well as their uses (e.g., as estrogen receptor degraders).
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A device includes a substrate and a ferroelectric layer supported by the substrate. The ferroelectric layer includes an alloy of a III-nitride material. The alloy includes a Group IIIB element. The substrate includes silicon.
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 2-hydroxybenzoic acid structure which function as sirtuin (e.g., SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7) inhibitors and/or degraders which function as effective therapeutic agents for treating, ameliorating, and preventing disorders associated with sirtuin activity (e.g., melanoma, Ewing sarcoma, malignant peripheral nerve sheath tumor, non-small cell lung cancer). In addition, this invention also relates to a new class of proteolysis-targeting chimeras (PROTACs) (as defined herein) which function as sirtuin inhibitors and/or degraders within cancer and/or immune cells. Pharmaceutical compositions comprising said compounds are also within the scope of the present invention.
C07C 65/03 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
A device for two, or more, color fluorescence imaging and methods for fluorescence-based corneal infection imaging. The device includes a frame including an aperture defining an aperture axis, and an imaging lens aligned with the aperture axis. A first image sensor with a first imaging axis aligned with the aperture axis and a second image sensor with a second imaging axis. The device includes a light source configured to emit a light along a source axis, a first beam splitter positioned at an intersection of the aperture axis and the source axis; and a second beam splitter positioned at an intersection of the first imaging axis and the second imaging axis.
An acoustic system includes a framework and a plurality of panes supported by the framework and arranged to form an acoustic surface. Each pane of the plurality of panes includes a face with a respective degree of curvature, the face having a respective number of holes, the number being zero or more. The degree of curvature and the number of holes differ across the plurality of panes to establish a monotonic gradient in an acoustic function across an extent of the acoustic surface.
G10K 11/16 - Methods or devices for protecting against, or for damping, noise or other acoustic waves in general
E04B 1/82 - Heat, sound or noise insulation, absorption, or reflection; Other building methods affording favourable thermal or acoustical conditions, e.g. accumulating of heat within walls specifically with respect to sound only
E04B 1/74 - Heat, sound or noise insulation, absorption, or reflection; Other building methods affording favourable thermal or acoustical conditions, e.g. accumulating of heat within walls
A flow-restricted pneumatic modulator (FRPM) assembly for a multidimensional gas chromatography system comprises a first y-shaped fluid connector having a first inlet receiving a stream from a first chromatographic column, a first channel having a flow resistor component and a first outlet, and a second channel having a second outlet in fluid communication a downstream bypass line. The FRPM assembly also has a second y-shaped fluid connector having a second inlet in fluid communication with the first outlet, a third inlet in communication with an auxiliary flow, and a third channel having a third outlet in fluid communication with a second chromatographic column. The FRPM assembly also has at least one flow control valve and can operate as an injector and a modulator to the second chromatographic column. Methods of chromatographic analysis of a fluid sample comprising one or more target analytes in a multidimensional chromatography system are also provided.
The disclosure relates to bioreactors, for example for biological treatment and, more specifically to bioreactor insert apparatus including temperature control and substance delivery elements. The temperature control elements include conduits to circulate a thermal or working fluid and provide a means to locally maintain a biofilm support and biofilm thereon at a temperature promoting growth of the biofilm microorganisms. The conduits for temperature control can further serve as substance delivery elements, providing a means for selective transport and biofilm-localized delivery of growth-promoting substances in the circulating thermal fluid. The temperature control and substance delivery elements can increase the overall reaction rate of the bioreactor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Techniques are presented for fabricating optoelectronic devices with integrated air bridges for improved efficiency. The optoelectronic device includes: a reflector disposed on the substrate; a spacer layer disposed on the reflector; and a thermophotovoltaic cell disposed on to the spacer layer, such that the spacer layer is arranged between the reflector and the thermophotovoltaic cell and the spacer layer includes a cavity which extends between the reflector and the thermophotovoltaic cell. Of note, the thermophotovoltaic cell is comprised of silicon material with one or more lateral p-n junctions formed therein.
H01L 31/054 - Optical elements directly associated or integrated with the PV cell, e.g. light-reflecting means or light-concentrating means
H01L 31/068 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PN homojunction type, e.g. bulk silicon PN homojunction solar cells or thin film polycrystalline silicon PN homojunction solar cells
An aortic septotomy device for cutting aortic tissue between a true lumen and a false lumen. The aortic septotomy device having a handle device having a jaw actuator member and an optional cutter actuator member; a distal head assembly having a pair of jaw members movable between an opened position and a clamping position and a cutting mechanism movable within a channel; and a sheath member extending from the handle device to the distal head assembly; wherein at least one of the pair of jaw members is movable in response to actuation of the jaw actuator member to selectively grasp aortic tissue, and the cutting mechanism is movable within the channel in response to actuation of the cutter actuator member to cut at least a portion of the aortic tissue while the pair of jaw members grasps the aortic tissue.
A wearable motion assistive device such as an electromechanical exoskeleton includes an actuator that circumscribes a natural or artificial portion of the body of a user when the user wears the device. The actuator includes an interior stator, an exterior rotor, and a bearing assembly, each of which may be segmented to permit the actuator to be installed around or be removed from around the portion of the user's where the device is worn. The bearing assembly includes a plurality of small roller bearings mounted on a carrier affixed to the stator and is segmented along the carrier between roller bearings.
A thruster includes a mass source, an ejection outlet, and a channel forming an ejection path from the mass source to the ejection outlet. Multiple annular current paths form loops such that current flow along the loops is transverse to ion flow along the ejection path. The current paths are driven by current supply circuitry to create a selected current distribution proximate to the channel
An electrospray thruster includes an emitter including an array of tips, each tip of the array of tips being configured to emit ionic liquid, and an extractor electrode spaced from the emitter and comprising a conductive film, the conductive film having a plurality of apertures, the plurality of apertures being aligned with the array of tips of the emitter. The conductive film has a thickness such that an electrical short between the extractor electrode and the ionic fluid emitted from a respective tip of the array of tips ablates a portion of the conductive film along the aperture of the plurality of apertures aligned with the respective tip of the array of tips
A photocatalytic device includes a substrate and an array of conductive projections supported by the substrate and extending outward from the substrate. Each conductive projection of the array of conductive projections has a semiconductor composition configured for charge carrier generation in response to solar radiation. Each conductive projection of the array of conductive projections is decorated with a co-catalyst arrangement. The cocatalyst arrangement includes gold and an oxide material.
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing electromagnetic waves
Provided herein are systems and methods for analysis of biological samples to identify biomarkers associated with nonalcoholic fatty liver disease. For example, provided herein are molecular signatures that find use in characterizing samples to facilitate research, drug discovery, and treatment associated with nonalcoholic fatty liver disease.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Provided herein are vaccine compositions and uses thereof. In particular, provided herein are synthetic viral-like structures (sVLSs) based vaccines and the use of such vaccines to prevent infection by a pathogen (e.g., viral pathogen).
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
The present disclosure relates to combination therapies for the treatment of cancer. In particular, the disclosure relates to combination therapy with a CXCR4 inhibitor and a taxane for the treatment of cancer. In some aspects, the disclosure relates to combination therapy with a CXCR4 inhibitor and a taxane for the treatment of tumors in the bone of a subject.
In an implementation, a nasopharyngeal airway device (100) includes an elongate body (102) having a distal end (104) and a proximal end (106). The elongate body defines a channel (108) extending along the elongate body. The elongate body has a wall (110) having a first portion (112) and a second portion (114). The first portion is thicker than the second portion to deter the elongate body from inwardly collapsing.
Systems and methods for object and material recognition are provided and include a hyperspectral infrared camera that captures a three-dimensional image of an object and black-body emissions data indicating a polarization of black-body radiation emitted from the object. An image processing device accesses a database of expected polarization signatures of black-body emissions from materials at different temperatures and determines a material of the object based on (i) the black-body emissions data indicating the polarization of the black-body radiation emitted from the object, (ii) an ambient temperature of the environment of the system, and (iii) the database of expected polarization signatures of black-body emissions from a plurality of materials for different temperatures.
G01J 5/59 - Radiation pyrometry, e.g. infrared or optical thermometry - Details thereof
G01J 4/04 - Polarimeters using electric detection means
G01N 21/71 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light thermally excited
62.
SEMICONDUCTOR HETEROSTRUCTURES WITH QUATERNARY III-NITRIDE ALLOY
A method includes of fabricating a heterostructure includes growing epitaxially, in a growth chamber, a first semiconductor layer of the heterostructure, the first semiconductor layer comprising a III-nitride semiconductor material, the first semiconductor layer being supported by a substrate, and, after growing the first semiconductor layer, growing epitaxially, in the growth chamber, a second semiconductor layer of the heterostructure such that the second semiconductor layer is supported by the first semiconductor layer, the second semiconductor layer comprising a quaternary or higher order III-nitride alloy. The quaternary or higher order III-nitride alloy comprises a group IIIB element
A probe assembly comprising a probe shank having a plurality of polymer layers. The plurality of polymer layers includes a first polymer layer and a second polymer layer. The first polymer layer and the second polymer layer sandwich one or more recording traces or one or more stimulating traces such that the first polymer layer, the second polymer layer, the one or more recording traces, and the one or more stimulating traces are configured to conform around an anatomical structure. A method of manufacturing involves treating the first polymer layer to increase a surface area on an adhesion portion of the first polymer layer. Another method of manufacturing involves monolithically fabricating a light emitting diode (LED) that is equal to or less than 500 square microns, and applying a polyimide layer to form a probe shank around the LED.
A method for forming an electrochemical device may comprise the steps of: (a) exposing electrode material particles to a lithium-containing precursor followed by an oxygen-containing precursor to form a coating on the electrode material particles; (b) forming a slurry comprising the coated electrode material particles; (c) casting the slurry to form a layer; (d) calendering the layer to form one or more electrodes (anode and/or cathode); (e) positioning a separator between the anode and the cathode to form a cell structure; and (f) positioning the cell structure in a liquid electrolyte, wherein the electrolyte is essentially free of a solvent that forms a solid electrolyte interphase on the anode and/or cathode. The method reduces the need for slow, costly preconditioning to be performed following lithium-ion battery cell assembly, and enables the use of ethylene carbonate-free electrolytes, thereby improving cycling stability at high voltages for lithium-ion batteries.
H01M 4/134 - Electrodes based on metals, Si or alloys
H01M 4/1393 - Processes of manufacture of electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
H01M 4/36 - Selection of substances as active materials, active masses, active liquids
H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
65.
SYSTEM AND METHOD FOR SIMULATING AN ENVIRONMENT FOR AUTONOMOUS VEHICLE TESTING
A system and method for safety testing a host autonomous vehicle (AV). This method includes: generating a trained machine learning (ML) agent and testing the host AV in an environment that includes one or more background vehicles configured to operate according to the trained ML agent. The ML agent is generated by: (i) obtaining a testing state model having non-safety-critical states and safety-critical states, (ii) editing the testing state model to obtain an edited testing state model that omits data concerning the non-safety- critical states, and (iii) training a ML agent using the edited state testing model so as to generate the trained ML agent.
Synthetic cellular support systems in the form of engineered extracellular matrices are provided. The cellular support system may include a three-dimensional scaffold structure comprising at least one void. At least one suspended fibril spans across the at least one void in the three-dimensional scaffold structure. The suspended fibril comprises at least one extracellular matrix protein, such as fibronectin, and at least one glycan, such as a hyaluronic acid. The suspended fibril is capable of supporting cells and promoting three-dimensional cellular growth. In various aspects, a plurality of suspended fibrils may span the void to form a three-dimensional suspended fibrillar network.
The present disclosure relates to modified tissue factor proteins and uses thereof. In some embodiments, the disclosure relates to modified human tissue factor proteins with increased clotting activity and uses thereof including in clotting tests, as topical hemostatic agents, and in methods of inducing tumor infarction.
The present disclosure provides dual functioning compounds, compositions, formulations, and methods for inducing or modulating an immune or inflammatory response and treating diseases or disorders (e.g., cancer, autoimmune diseases, inflammatory diseases, and infectious diseases) with the compounds or compositions thereof. In particular disclosed herein are dual functioning compounds comprising a stimulator of interferon (IFN) genes (STING) agonist moiety and a second active moiety selected from an indoleamine 2,3-dioxygenase (IDO) inhibitor and phosphatidylinositol 3‑kinase (PI3K) inhibitor, and compositions and formulations thereof.
C07D 333/50 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
C07D 333/56 - Radicals substituted by oxygen atoms
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
The present disclosure provides compounds, compositions, formulations, and methods for delivery of active agents (e.g., nucleic acid). In particular, the present disclosure provides modified lipids (e.g., lipids conjugated with 1-methyl-D-tryptophan) for use in delivery of active agents and compositions and vaccines thereof.
The present disclosure provides STING agonists, and compositions, formulations. and methods for treating diseases or disorders (e.g., cancer, inflammatory diseases, autoimmune diseases, and infectious diseases) with the STING agonists or compositions thereof.
C07D 333/60 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 409/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
A61P 35/04 - Antineoplastic agents specific for metastasis
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
71.
COMPOSITIONS AND METHODS FOR TREATING EYE DISORDERS
Provided herein are compositions and methods for treating eye disorders. In particular, provided herein are compositions and methods for treating and preventing retinal pigment epithelium (RPE) epithelial-to-mesenchymal transition (EMT), epiretinal membrane (ERM), and/or proliferative vitreoretinopathy.
Nanostructured chiral microparticles with bowtie shape having widely variable pitch, size, thickness and length are provided. The self-limited assembly of anisotropic building blocks makes possible high synthetic reproducibility, size monodispersity and computational predictability of their geometries for different assembly conditions. They display multiple strong circular dichroism peaks originating from absorptive and scattering phenomena. Unlike classical chiral molecules, these particles display a continuum of Osipov-Pickup-Dunmur chirality measures that exponentially correlate with the spectral positions of the circular dichroism peaks. Bowtie particles with variable polarization rotation were utilized in printing photonically active metasurfaces with spectrally tunable positive/negative polarization signatures for light detection and ranging (LIDAR) devices.
The following relates generally to administering and delivering medications to patients. In some embodiments, an in-home appliance may place an ingestible ingredient (e.g., an active pharmaceutical ingredient (API) of a medication) on a physical substrate to create a distributable/retrievable object, which is distributed to a subject. The subject may then consume at least a portion of the ingestible ingredient, and then return at least a portion of the distributable/retrievable object to the appliance. The appliance, upon receiving the object, can subsequently trigger secondary actions, including logging the consumption of the dose; authorizing the next dose to override security measures which would otherwise block access to additional doses; analyzing the returned object for biometrics or remaining amount of ingestible ingredients, etc. Logged data will populate a software database on the cloud which can integrate with any number of internal and external systems, triggering programmable actions within a closed-loop architecture.
G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
74.
PHOTOCATALYTIC WATER SPLITTING WITH SEPARATE H2 AND O2 PRODUCTION
A water splitting system includes a hydrogen production chamber including a hydrogen production port, an oxygen production chamber including an oxygen collection port, an ion exchange membrane coupling the hydrogen production chamber and the oxygen production chamber, and a photocatalytic structure including a first catalytic portion disposed in the hydrogen production chamber and a second catalytic portion disposed in the oxygen production chamber. The first catalytic portion is configured for production of hydrogen via the hydrogen production port. The second catalytic portion is configured for production of oxygen via the oxygen production port.
Methods and systems to identify actual esophageal tissue changes (e.g., during cardiac ablation) are disclosed. An example system includes a probe and a data analysis unit. The probe is configured for positioning in a patient's esophagus and includes a sheath, and a plurality of tendrils extendible by a user from an end of the sheath within the esophagus. Each tendril has a plurality of nodes spaced apart along the tendril, wherein each node of the plurality of nodes is configured to be used to introduce signals into esophageal tissue and/or receive signals affected by esophageal tissue. The data analysis unit is configured to determine a value of a characteristic indicative of actual change to esophageal tissue between two nodes based on a signal received using at least one of the nodes, and to provide an indication of actual esophageal tissue change based on the determined value.
Provided herein are systems and methods for determining a subject's risk of fibromuscular dysplasia (FMD) and/or abdominal aortic aneurysm (AAA), and methods of treatment and symptom management based thereon.
Provided herein are methods, compositions, kits and systems for regulation of peptide function. In particular, provided herein are methods, compositions, kits and systems comprising nucleic acid constructs and fusion proteins comprising chemically-activated protein domains (CAPs) that regulate the activity of a fused peptide in the presence of a ligand.
A61K 31/5355 - Non-condensed oxazines containing further heterocyclic rings
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/62 - DNA sequences coding for fusion proteins
The present disclosure provides JAK inhibitor analogs, and compositions and methods thereof for treating diseases or disorders (e.g., inflammatory bowel disease and ulcerative colitis).
In an example method for detecting indole, an indole producing bacterium, or an indole producing chemical, a polymeric detection tool is exposed to a sample and the polymeric detection tool is monitored for a red color change. The polymeric detection tool includes an acidic and oxygen soluble polymer and a nitrosation agent impregnated in walls of the acidic and oxygen soluble polymer. This example method can be used for detecting an indole producing bacterium in a body fluid sample.
A medical device includes a needle coupled with a syringe and is configured to feed a guidewire through the needle and out of a tip of the needle with only one hand and without decoupling the needle from the syringe. A user can feed the guidewire through the device using the same hand holding the device and using the same hand that applies a vacuum in the syringe. The device frees up the user's other hand to control the position of an ultrasonic transducer to continuously visualize all steps of vascular access, including feeding of the guidewire into the blood vessel or other hollow cavity of a patient.
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Zhang, Xuqing
Wang, Shaomeng
Kirchhoff, Paul
Abstract
Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
The present disclosure provides methods, devices, and kits useful for screening or characterizing extracellular vesicles (e.g., exosomes) by monitoring cell-type specific extracellular vesicle uptake and/or cells' feedback responses.
A VIVACE converter to harness energy from currents as well as from waves-that is, the present teachings provide a method and apparatus to collect energy from both currents and waves - using the same physical components. The present teachings are particularly useful in that either currents and/or waves may exist on their own nearly everywhere in the oceans and frequently coexist.
F03B 17/06 - Other machines or engines using liquid flow, e.g. of swinging-flap type
F03B 13/26 - Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using tide energy
F03B 13/20 - Adaptations of machines or engines for special use; Combinations of machines or engines with driving or driven apparatus; Power stations or aggregates characterised by using wave or tide energy using wave energy using the relative movement between a wave-operated member and another member wherein both members are movable relative to the sea bed or shore
84.
HETEROSTRUCTURES WITH NANOSTRUCTURES OF LAYERED MATERIAL
A method of fabricating a heterostructure includes forming a layered material structure such that the layered material structure has an edge, and growing epitaxially a nanostructure of layered material laterally from the edge of the layered material structure such that an inplane interface between the layered material structure and the nanostructure is defined. Growing the nanostructure is implemented at a growth temperature sufficiently near a decomposition temperature of the layered material such that a nucleation interface of the nanostructure has a single atomic configuration.
The present disclosure provides an exoskeleton mechanism for supporting a joint. The exoskeleton mechanism includes a brace having a first arm and a support arm, the support arm pivotably connected to the first arm. The exoskeleton mechanism further includes a spring secured to the first arm, the spring having a first length at an equilibrium position and a second length at a displaced position, a spring force generated by the spring when the spring is in the displaced position. Additionally, the exoskeleton mechanism has a cable having a first end and a second end, the first end coupled to the support arm and the second end coupled to the spring such that rotation of the support arm relative to the first arm causes the spring to move to the displaced position and the spring force is transferred to the support arm.
Systems and methods for fabricating an adjustable width kirigami structure for tissue fabrication and testing are disclosed. An example method includes forming, by a laser cutting device, at least two kirigami structure substrates that include a plurality of bendable pillars. The example method further includes bending each of the plurality of bendable pillars to an erected position for each of the at least two kirigami structure substrates. The example method further includes layering a first kirigami structure substrate of the at least two kirigami structure substrates over a second kirigami structure substrate of the at least two kirigami structure substrates, such that the first kirigami structure substrate is antiparallel relative to the second kirigami structure substrate, to generate an adjustable width kirigami structure.
ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (USA)
Inventor
Chen, Zhixiang
Rej, Rohan
Zhang, Xuqing
Bai, Longchuan
Kirchhoff, Paul
Wang, Shaomeng
Abstract
Described herein are compounds of Formulae I' and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as IKZF2 degraders).
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61P 5/00 - Drugs for disorders of the endocrine system
Gas chromatography (GC) relies on the interaction of vapor molecules with the stationary phase coated on the column inner wall to separate different vapor molecules. Here, graphene is integrated as the ultrathin and electrically tunable stationary phase within a GC column. Graphene has different interactions with different vapor molecules, which leads to separation of those vapor molecules. In addition, by configuring graphene into a field effect transistor (FET) design, the molecule-graphene interaction can be controlled or tuned by adjusting the graphene Fermi level through the FET gate voltage. As a result, the binding energy between graphene and adsorbed vapor molecules can be tuned and hence the elution time and/or elution order of vapor molecules can be changed.
A method for detecting plant evapotranspiration includes: detecting, by an evapotranspiration (ET) sensor arranged in a canopy of a plant, a speed of air flowing through the canopy of plant, a temperature of the air and a relative humidity of the air over a plurality of time intervals; calculating, by a processor, an estimated mass flux of the air using at least one of a convective mass transfer (CMT) model, a mass balance (MB) model, or an empirical (EM) model; determining, by the processor, a plant scaling coefficient; integrating, by the processor, the estimated mass flux of the air over the plurality of time intervals to obtain a running sum; and multiplying, by the processor, the running sum by the plant scaling coefficient to determine an estimated evapotranspiration of the plant.
A light communication system, receiver, and method for synchronizing a receiver with a transmitter so as to decode a data input stream transmitted by the transmitter and received at the receiver. The method includes: receiving a data input stream at a receiver, the data input stream having a first data rate that is set based on a transmitter clock rate; generating a wave; obtaining a phase error between the data input stream and the generated wave; determining a synchronized clock rate by using the phase error to adjust the frequency of the generated wave so as to match the frequency of the generated wave to the transmitter clock rate of the data input stream; and using the synchronized clock rate to decode the data input stream so as to obtain data encoded in the data input stream.
H04B 10/112 - Line-of-sight transmission over an extended range
H04L 7/00 - Arrangements for synchronising receiver with transmitter
H04L 7/033 - Speed or phase control by the received code signals, the signals containing no special synchronisation information using the transitions of the received signal to control the phase of the synchronising-signal- generating means, e.g. using a phase-locked loop
92.
COMPOSITIONS AND METHODS FOR ANALYSIS, DETECTION, AND TREATMENT OF MULTIPLE SCLEROSIS
The present disclosure relates to materials and methods for prognostic classification of multiple sclerosis patients. In particular, provided herein are biomarkers and methods of uses thereof for stratifying patients with multiple sclerosis. The methods described herein facilitate selection of an appropriate treatment for a subject.
A device includes a substrate and a heterostructure supported by the substrate. The heterostructure includes a set of quantum dot structures, each quantum dot structure of the set of quantum dot structures including a semiconductor material, and a layered material disposed between the set of quantum dot structures and the substrate. The layered material includes a plurality of monolayers such that adjacent monolayers of the plurality of monolayers are bonded to one another via van der Waals forces, and the semiconductor material of each quantum dot structure of the set of quantum dot structures exhibits bonding via van der Waals forces.
G11C 13/04 - Digital stores characterised by the use of storage elements not covered by groups , , or using optical elements
H01L 31/02 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof - Details
H01L 31/10 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by at least one potential-jump barrier or surface barrier, e.g. phototransistors
H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
94.
DURABLE OMNIPHOBIC ELASTOMERIC COATINGS AND METHODS FOR PREPARING THE SAME
A durable solid and liquid repellant material is provided having an elastomeric matrix with a plurality of lubricating domains distributed therein formed by a partial crosslinking reaction between an elastomeric precursor having a first reactive functional group and a polyol having a second reactive functional group. The polyol has a limited solubility circle. The first reactive functional group is selected from the group consisting of: alkene, amine, carboxylic acid, hydroxyl, isocyanate, and combinations thereof and the second reactive group is selected from the group consisting of: amine, carboxylic acid, hydroxyl group, and combinations thereof. The partially crosslinked elastomeric matrix has a crosslink density of greater than or equal to about 200 mol/m3 and less than or equal to about 2,000 mol/m3. Methods for forming the durable solid and liquid repellant material are also provided.
C09K 3/18 - Materials not provided for elsewhere for application to surface to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
In one aspect, a specimen holder includes a first end configured to attach to a cooling device and a second end configured to be inserted into a microscope; a section with a sample tip at the second end; an interface between the first end configured to attach to the cooling device and the section with the sample tip; and an internal thermal connection section configured to be in thermal contact with a cold finger of the cooling device when the specimen holder is attached to the cooling device and extending through the section with the sample tip to the sample tip.
A device includes a substrate and a semiconductor heterostructure supported by the substrate. The semiconductor heterostructure includes a first semiconductor layer supported by the substrate and including a first III-nitride semiconductor material, and a second semiconductor layer supported by the first semiconductor layer and including a second III-nitride semiconductor material. The second III-nitride semiconductor material includes scandium. The first and second semiconductor layers are nitrogen-polar.
H01L 29/20 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds
H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
H01L 29/201 - Semiconductor bodies characterised by the materials of which they are formed including, apart from doping materials or other impurities, only AIIIBV compounds including two or more compounds
97.
USER ELEMENT TECHNIQUE FOR ENABLING COARSE-MODEL/HIGH-FIDELITY COMPUTER-AIDED ENGINEERING DURABILITY EVALUATION OF SPOT-JOINED STRUCTURES
A method for modeling joints using User Element (UEL) techniques by analytically eliminating a series of internal degrees of freedom for representing actual weld or joint stiffness in structures. The resulting formulation is in closed-forms enabling computational accuracy and simplicity for structural applications. For spot joint, the detailed ring type of finite elements required to achieve a reasonable accuracy can be replaced by a simple finite element mesh using just four user elements. The UEL joint modeling method offers accurate stress calculation results by comparing with the mesh-insensitive structural stress method coupled with a detailed explicit joint representation of joints. The UEL method can also be applied for modeling seam welded joints, e.g., MIG, laser, and friction stir welds. The explicit representation of weld fillet geometry required by existing methods is no longer needed by the UEL plate/shell elements without losing any accuracy.
A method for monitoring the airspace around an aircraft or the road, runway, taxiway, movement area condition or any other object or surface of interest ahead of a vehicle, even in inclement weather is disclosed. The present teachings provide a system for characterizing cloud drops, cloud ice particles, other hydrometeors such drizzle, rain or falling snow, and for distinguishing dry surfaces from those covered by water, snow, frost, and various types of ice even when they cover only a fraction of the field of view of the road condition monitoring system, even in inclement weather.
G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
G01N 21/25 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
A die assembly includes an inflow end, an outflow end opposite the inflow end, and an internal cavity extending from the inflow end to the outflow end. The die assembly also includes an internal mandrel disposed within the internal cavity. The internal mandrel has an end proximate to the outflow end of the die assembly. The die assembly also includes an internal cooling channel within the internal mandrel. The internal cooling channel has an outlet at or near the end of the internal mandrel.
in vitroin vitro methods for production of Sertoli cells and related organoids. The Sertoli cells and testis like organoids may be used for therapeutic purposes including facilitation of the production of spermatogonia from pro-spermatogonia stem cells.
patents
